AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10984368
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) 200 microg once daily
Trial: 11449205
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate 84 microg twice daily
Trial: 11449205
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate or BUD
Trial: 2890805
Drug: Vi capsular
RxNorm normalized name: typhoid vaccine VI capsular polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi capsular polysaccharide (CPS) vaccine (25 micrograms, single intramuscular injection)
Trial: 17899018
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg morphine
Trial: 23614336
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without telemetric monitoring (Control Group)
Trial: 3330992
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (30-60 mg/day)
Trial: 3330992
Drug: Hydrochlorothiazide (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25-50 mg/day)
Trial: 29381560
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (3-g pill daily for 12 weeks, containing 1.8-g eicosapentaenoic acid and 1.2-mg docosapentaenoic acid)
Trial: 29381560
Drug: Placebo (44.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (44.8 mg of high oleic safflower oil)
Trial: 27317632
Drug: α1‐adrenergic blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α1‐adrenergic blockade (oral Prazosin, 0.05 mg/kg)
Trial: 26215644
Drug: Early, individually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early, individually tailored occupational rehabilitation intervention using acceptance and commitment therapy dialogue and individual-placement-and-support-inspired tools.
Trial: 24124710
Drug: Mannitol dosage
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol dosage in Groups A, B, C
Trial: 18339160
Drug: Total Intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Intravenous Anaesthesia (TIVA) using propofol and remifentanil
Trial: 9579448
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 50 microg/day
Trial: 15641867
Drug: Ziprasidone 40
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 40 to 80 mg b.i.d.
Trial: 15641867
Drug: Risperidone 3
RxNorm normalized name: risperidone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 3 to 5 mg b.i.d.
Trial: 11384791
Drug: Benzodiazepines administered
RxNorm normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepines administered by paramedics
Trial: 9788422
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control group (no prophylactic therapy)
Trial: 29769507
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (1μg/kg) with intravenous fentanyl (1μg/kg)
Trial: 29769507
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (1μg/kg) with intravenous fentanyl (1μg/kg)
Trial: 29769507
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (2μg/kg)
Trial: 10709884
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula with 13 g l(‐1) of protein
Trial: 10709884
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula with 15 g l(‐1) of protein
Trial: 10709884
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula with 18/20 g l(‐1) of protein
Trial: 8684510
Drug: Physostigmine capsules
DrugBank: Physostigmine (DB00981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine capsules (up to 10 mg per day)
Trial: 8684510
Drug: Physostigmine patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine patch (transdermal application)
Trial: 1627368
Drug: 75 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 doxorubicin every 3 weeks for four courses (arm 1)
Trial: 1627368
Drug: 25 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m2 weekly for 12 courses (arm 2)
Trial: 22895810
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide (500 mg/day)
Trial: 22895810
Drug: L-carnitine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (500 mg/day)
Trial: 22895810
Drug: Mg-L-carnitine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg-L-carnitine (500 mg/day magnesium and 500 mg/day L-carnitine)
Trial: 19800827
Drug: Calculated based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated based on fixed absorbed dose of 400 Gy in GR3
Trial: 19800827
Drug: Calculated based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated based on fixed absorbed dose of 100 Gy in GR1
Trial: 19800827
Drug: Average activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average activity administered to GR2
Trial: 19800827
Drug: Average activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average activity administered to GR3
Trial: 19800827
Drug: Thyroid absorbed
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid absorbed dose in GR2
Trial: 19800827
Drug: Thyroid absorbed
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid absorbed dose in GR3
Trial: 18077922
Drug: Ointment containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment containing Mahonia aquifolium, Viola tricolor and Centella asiatica
Trial: 18077922
Drug: Base cream
RxNorm normalized name: U-Base Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Base cream (vehicle)
Trial: 18077922
Drug: Ointment containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment containing Mahonia aquifolium, Viola tricolor and Centella asiatica (in cold and dry conditions)
Trial: 12399266
Drug: Betaine supplementation
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine supplementation (6 g/d)
Trial: 7755536
Drug: Eight-session telephone
RxNorm normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight-session telephone behavior therapy program
Trial: 7755536
Drug: Telephone behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone behavior therapy
Trial: 6270809
Drug: Nicergoline (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (2.5 mg i.v.)
Trial: 24157401
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OT) and vasopressin (AVP)
Trial: 16011816
Drug: Vardenafil 5
RxNorm normalized name: vardenafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 5 mg, 10 mg, or 20 mg
Trial: 9860409
Drug: Oral norfloxacin
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral norfloxacin 400 mg/12 h for 7 days
Trial: 9860409
Drug: Norfloxacin plus
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norfloxacin plus intravenous ceftriaxone 2 g daily during the first 3 days of admission
Trial: 9860409
Drug: Norfloxacin plus
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norfloxacin plus intravenous ceftriaxone
Trial: 2762182
Drug: APF foam
RxNorm normalized name: SODIUM FLUORIDE 1.5498 g in 126 g ORAL AEROSOL, FOAM [Ionite APF Foam]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APF foam (0.9 g)
Trial: 2762182
Drug: APF gel
RxNorm normalized name: APF Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APF gel (4 g)
Trial: 1155873
Drug: Continuous agar
RxNorm normalized name: Agar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous agar oral administration, 125 mg before each of the seven formula feedings
Trial: 1155873
Drug: Discontinuous agar
RxNorm normalized name: Agar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuous agar administration, 250 mg before three of the seven formula feedings
Trial: 28458115
Drug: Pregnenolone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone treatment (n=6)
Trial: 28458115
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (n=5)
Trial: 20948432
Drug: Olanzapine LAI
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine LAI 300 mg/2 weeks
Trial: 20948432
Drug: Olanzapine LAI
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine LAI 150 mg/2 weeks
Trial: 20948432
Drug: Olanzapine LAI
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine LAI 405 mg/4 weeks
Trial: 17315804
Drug: Oral-health workshop
RxNorm normalized name: Healthy Mama Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-health workshop
Trial: 11822223
Drug: Azithromycin 1
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1 g once daily (single dose)
Trial: 9762946
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine (2 g amino acid/M2/dose twice daily)
Trial: 28419204
Drug: Sabin‐IPV high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabin‐IPV high dose
Trial: 28419204
Drug: Sabin‐IPV medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabin‐IPV medium dose
Trial: 28419204
Drug: Sabin‐IPV low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabin‐IPV low dose
Trial: 28419204
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral polio vaccine
Trial: 25923490
Drug: Haloperidol (low-dose)
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol (low-dose)
Trial: 22236169
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide (CH) intracanal medication for 14 days
Trial: 22133165
Drug: Non-pharmacological multicomponent
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmacological multicomponent group therapy (MAKS) - motor stimulation, practice in activities of daily living, cognitive stimulation, conducted in groups of ten patients for 2 hours, 6 days a week for 12 months.
Trial: 19758253
Drug: Water solutions
RxNorm normalized name: water Irrigation Solution
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water solutions containing 1.5% SLS
Trial: 15249273
Drug: Donepezil (high-dose)
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil (high-dose)
Trial: 30326124
Drug: Low-dose theophylline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose theophylline (200 mg once or twice per day)
Trial: 15219522
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin 1000 mg
Trial: 15219522
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin 1500 mg
Trial: 15219522
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin 2000 mg
Trial: 15219522
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin 3000 mg
Trial: 11285986
Drug: hCG administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG administration with oocyte collection intervals of 33-41 hours
Trial: 26950065
Drug: hCG administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG administration
Trial: 9676345
Drug: Theophylline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (500 mg b.i.d.)
Trial: 3209607
Drug: Cefotaxime (CTX)
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotaxime (CTX) - 4 doses for 2 days
Trial: 3209607
Drug: Benzylpenicillin combined
RxNorm normalized name: benzylpenicillin
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzylpenicillin combined with cloxacillin (BPC) - 6 doses for 3 days
Trial: 3209607
Drug: Cefotaxime with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime with additional antibiotics for fever (CTX-ADD)
Trial: 3209607
Drug: Benzylpenicillin combined
RxNorm normalized name: benzylpenicillin
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzylpenicillin combined with cloxacillin with additional antibiotics for fever (BPC-ADD)
Trial: 30642737
Drug: Probiotic plus
RxNorm normalized name: CVS Advanced Probiotic Plus Fiber Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic plus selenium (200 μg/day selenium + 2 × 10^9 CFU/day of Lactobacillus acidophilus, Bifidobacterium bifidum, and Bifidobacterium longum)
Trial: 28315596
Drug: Strengthening exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strengthening exercises for hip and trunk muscles (three weekly sessions for eight weeks)
Trial: 25562195
Drug: Yerba mate
RxNorm normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yerba mate tea (5 g/day) for 6 weeks
Trial: 25562195
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 g/day) for 6 weeks
Trial: 21999374
Drug: Autologous stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous stem cells (ASC) injection
Trial: 21999374
Drug: Traditional compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional compression sleeve therapy (CST)
Trial: 17130417
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group from the clinical phase III US Insulin‐like Growth Factor‐I Trial
Trial: 9269013
Drug: Hydroxyapatite-coated titanium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyapatite-coated titanium plasma-sprayed implants
Trial: 9269013
Drug: Titanium plasma-sprayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium plasma-sprayed implants
Trial: 24046411
Drug: 20 nmol
RxNorm normalized name: QUINAPRIL HYDROCHLORIDE 20 nmol / HYDROCHLOROTHIAZIDE 12.5 mg ORAL TABLET, FILM COATED [Quinapril Hydrochloride and Hydrochlorothiazide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 nmol of c-di-GMP administered intramuscularly (IM) in conjunction with penicillin G for 5 days
Trial: 24046411
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with saline and penicillin G
Trial: 24046411
Drug: Gavage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gavage treatment with 20 nmol of c-di-GMP in conjunction with penicillin G
Trial: 24046411
Drug: IM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM treatment with c-di-GMP
Trial: 19674132
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy plus bismuth subcitrate (lansoprazole 30 mg b.i.d., amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d., bismuth subcitrate 300 mg q.i.d. for 14 days)
Trial: 19674132
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy plus bismuth subcitrate and vitamins C (500 mg b.i.d.) and E (200 IU b.i.d. for 30 days)
Trial: 17175645
Drug: Shengmai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shengmai injection (40 ml) with 250 ml 50 g/L glucose solution for 3 days, 1 time per day
Trial: 17175645
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with 290 ml 50 g/L glucose injection liquid for 3 days, 1 time per day
Trial: 11353932
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion (10 ng/kg/min for 1 hour)
Trial: 11353932
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide (NO) inhalation (20 ppm for 1 hour)
Trial: 9398951
Drug: 0.05 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg.kg‐1 rocuronium + 1.5 mg.kg‐1 succinylcholine
Trial: 9398951
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline followed by 1.0 mg.kg‐1 succinylcholine
Trial: 8435812
Drug: Accelerated hyperfractionated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hyperfractionated radiation therapy at 48 Gy
Trial: 8435812
Drug: Accelerated hyperfractionated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hyperfractionated radiation therapy at 54.4 Gy
Trial: 8435812
Drug: Accelerated hyperfractionated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hyperfractionated radiation therapy at 64 Gy
Trial: 8435812
Drug: Accelerated hyperfractionated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hyperfractionated radiation therapy at 70.4 Gy
Trial: 26553413
Drug: Endourethral collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endourethral collagen type 2 injection
Trial: 26553413
Drug: Endourethral saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endourethral saline water injection
Trial: 22648218
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide 5%/clindamycin 1% gel (BPO/C)
Trial: 22648218
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% gel (AP)
Trial: 17525166
Drug: valdecoxib 20
RxNorm normalized name: valdecoxib 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valdecoxib 20 mg bid
Trial: 17525166
Drug: valdecoxib 40
RxNorm normalized name: valdecoxib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg qd
Trial: 15302981
Drug: eprosartan 600
RxNorm normalized name: eprosartan 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eprosartan 600 mg
Trial: 12049152
Drug: Tofu +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofu + Orange Juice (6 oz tofu + 303 mg vitamin C/day)
Trial: 9834279
Drug: Pefloxacin 400
RxNorm normalized name: pefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin 400 mg twice daily for 2 weeks
Trial: 9834279
Drug: Imipenem 500
RxNorm normalized name: imipenem 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem 500 mg three times daily for 2 weeks
Trial: 1777912
Drug: Ionic contrast
RxNorm normalized name: IONIC CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ionic contrast agent
Trial: 1777912
Drug: Nonionic contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonionic contrast agent
Trial: 2552740
Drug: 300 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 micrograms immune globulin anti-D administered prenatally
Trial: 31254681
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment at TE3 and TE5 for 30 minutes